Boehringer Ingelheim Venture Fund followed an investment last September by contributing to a $26.8m round for the bacteria-based cancer drug developer.

Santen Ventures co-led a series B round to bring TAU faculty-founded Belkin Laser's funding total to $16.3m.

Santen Ventures co-led a series B round also backed by C-Mer Eye Care and BioLight Life Science to bring Belkin Laser's funding total to $16.3m.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

The gene therapy developer has followed a $120m round co-led by Novo three weeks ago by filing to go public on the Nasdaq Global Select Market.

Fidelity led a series C round for haematology and cancer therapy developer Antengene, whose corporate shareholders include Celgene, Taikang, Tigermed and WuXi AppTec.

Novo-backed immuno-oncology drug developer Checkmate Pharmaceuticals has filed to go public a month after its last funding round.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

GlaxoSmithKline is paying $176m for a 10% stake in University of Tübingen's RNA drug developer in connection with a strategic partnership agreement.

UC Berkeley-linked cell biology technology developer Berkeley Lights floated in a $178m offering and its shares almost tripled in price on their first day of trading.